Dutch biotech Fornix BioSciences (FORBI.AS) said on Thursday it will sell its medical supplies unit Laprolan to Rochester Medical (ROCM.O) for 10.35 million euros ($13.5 million), largely completing the company's unwinding. The sale completes a series of divestments Fornix launched early last year after it lost a crucial court ruling that prevented insurers from reimbursing patients for Fornix's grass allergy product, severely limiting the firm's growth potential. Fornix has since sold the company's allergy unit to Danish-based drugs firm ALK-Abello (ALKb.CO) for 19.6 million euros and has sold its German unit Artu Biologicals to Rolke Pharma earlier this month for a minimal sum. "We are convinced that we have found in Rochester Medical the right partner to ensure a continued solid basis for Laprolan, its customers and employees and pleased to have completed the planned divestments", Fornix's supervisory board chairman Erik van de Merwe said in a statement.
Source